Visualisation of in vivo protein synthesis during mycobacterial infection through [68Ga]Ga-DOTA-puromycin µPET/MRI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F24%3A00598051" target="_blank" >RIV/61389005:_____/24:00598051 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1038/s41598-024-70200-4" target="_blank" >https://doi.org/10.1038/s41598-024-70200-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-024-70200-4" target="_blank" >10.1038/s41598-024-70200-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Visualisation of in vivo protein synthesis during mycobacterial infection through [68Ga]Ga-DOTA-puromycin µPET/MRI

Popis výsledku v původním jazyce

Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [Ga-68]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (mu PET/MRI). The radiopharmaceutical was produced by previously published and validated methods. [Ga-68]Ga-DOTA-Puromycin imaging was performed on severe immunodeficient mice infected with acille Calmette-Guérin-derived M. Bovis (BCG). Acute and chronic infection stages were examined by mu PET/MRI. A follow-up group of animals acted as controls (animals bearing S. aureus-derived infection and sterile inflammation) to assess tracer selectivity. [Ga-68]Ga-DOTA-puromycin-mu PET/MRI images revealed the acute, widespread infection within the right upper shoulder and armpit. Also, [Ga-68]Ga-DOTA-puromycin signal sensitivity measured after a 12-week period was lower than that of [F-18]FDG-PET in the same animals. A suitable correlation between normalised uptake values (NUV) and gold standard histopathological analysis confirms accurate tracer accumulation in viable bacteria. The radiopharmaceutical showed infection selectivity over inflammation but accumulated in both M. Bovis and S. Aureus, lacking pathogen specificity. Overall, [Ga-68]Ga-DOTA-puromycin exhibits potential as a tool for non-invasive protein synthesis visualization, albeit without pathogen selectivity.

Název v anglickém jazyce

Visualisation of in vivo protein synthesis during mycobacterial infection through [68Ga]Ga-DOTA-puromycin µPET/MRI

Popis výsledku anglicky

Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [Ga-68]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (mu PET/MRI). The radiopharmaceutical was produced by previously published and validated methods. [Ga-68]Ga-DOTA-Puromycin imaging was performed on severe immunodeficient mice infected with acille Calmette-Guérin-derived M. Bovis (BCG). Acute and chronic infection stages were examined by mu PET/MRI. A follow-up group of animals acted as controls (animals bearing S. aureus-derived infection and sterile inflammation) to assess tracer selectivity. [Ga-68]Ga-DOTA-puromycin-mu PET/MRI images revealed the acute, widespread infection within the right upper shoulder and armpit. Also, [Ga-68]Ga-DOTA-puromycin signal sensitivity measured after a 12-week period was lower than that of [F-18]FDG-PET in the same animals. A suitable correlation between normalised uptake values (NUV) and gold standard histopathological analysis confirms accurate tracer accumulation in viable bacteria. The radiopharmaceutical showed infection selectivity over inflammation but accumulated in both M. Bovis and S. Aureus, lacking pathogen specificity. Overall, [Ga-68]Ga-DOTA-puromycin exhibits potential as a tool for non-invasive protein synthesis visualization, albeit without pathogen selectivity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scientific Reports

ISSN

2045-2322

e-ISSN

2045-2322

Svazek periodika

14

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

19250

Kód UT WoS článku

001295308500120

EID výsledku v databázi Scopus

2-s2.0-85201534654